Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressant-refractory depression.
Tulen
Joke H M
JH
Volkers
Anita C
AC
van den Broek
Walter W
WW
Bruijn
Jan A
JA
D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D004351:Drug Resistance; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced* / Q000503:physiopathology; D007099:Imipramine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects*; D010624:Phenelzine / Q000009:adverse effects*; D011569:Psychiatric Status Rating Scales; D014191:Tranylcypromine / Q000009:adverse effects*; D016896:Treatment Outcome
D000928:Antidepressive Agents; D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D008996:Monoamine Oxidase Inhibitors; D014191:Tranylcypromine; D010624:Phenelzine; D016666:Fluvoxamine; D007099:Imipramine